Advancing Treatment in ER-Positive, HER2-Negative Advanced Breast Cancer: Efficacy of Giredestrant Plus Everolimus
A phase 3 trial demonstrates that the oral combination of giredestrant and everolimus significantly improves progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer post-CDK4/6 inhibitor therapy, especially in ESR1-mutated tumors, with a manageable safety profile.